Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | RCE1 | Q9Y256 | 5/20 | 0.43 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | ICMT | O60725 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138605 | 0.77 | PTPN22 (0.54) | LDHARCE1PTPN22HSP90AA1ICMT | |
| SCHEMBL17540622 | 0.75 | PTPN22 (0.52) | LDHARCE1PTPN22HSP90AA1ICMT | |
| SCHEMBL8759057 | 0.71 | RCE1 (0.58) | LDHARCE1PTPN22HSP90AA1 | |
| SCHEMBL9988192 | 0.71 | LDHA (0.53) | LDHARCE1PTPN22HSP90AA1 | |
| SCHEMBL11374363 | 0.71 | TSHR (0.53) | LDHARCE1PTPN22HSP90AA1PSEN1 | |
| SCHEMBL11102310 | 0.70 | PTPN22 (0.46) | LDHARCE1PTPN22HSP90AA1ICMT | |
| SCHEMBL7305915 | 0.70 | PTPN22 (0.54) | LDHARCE1PTPN22HSP90AA1ALDH1A1 | |
| SCHEMBL5596420 | 0.70 | PTPN22 (0.54) | LDHARCE1PTPN22HSP90AA1ALDH1A1 | |
| SCHEMBL8384862 | 0.69 | RCE1 (0.44) | RCE1PTPN22PSEN1PSEN2APH1B | |
| SCHEMBL431650 | 0.68 | LDHA (0.69) | LDHAPTPN22MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12163968-B2 | Preparation of nucleated RBC (NRBC) analogs for use as reference hematology controls in automated hematology analyzers | BIO-RAD LABORATORIES, INC. (US) | 2024-12-10 | — | — | US | claimed |
| US-12163968-B2 | Preparation of nucleated RBC (NRBC) analogs for use as reference hematology controls in automated hematology analyzers | BIO-RAD LABORATORIES, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4208021-A1 | PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS | Bio-Rad Laboratories, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022051443-A1 | PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS | BIO-RAD LABORATORIES, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20220065878-A1 | PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS | BIO-RAD LABORATORIES, INC. | 2022-03-03 | — | — | US | disclosed |
| US-8114580-B2 | Simulation of normal fresh blood platelets for reference control | BIO-RAD LABORATORIES, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2376908-A1 | SIMULATION OF NORMAL FRESH BLOOD PLATELETS | Bio-Rad Laboratories, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010083130-A1 | SIMULATION OF NORMAL FRESH BLOOD PLATELETS | BIO-RAD LABORATORIES, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100178647-A1 | SIMULATION OF NORMAL FRESH BLOOD PLATELETS | BIO-RAD LABORATORIES, INC. (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178647-A1 | SIMULATION OF NORMAL FRESH BLOOD PLATELETS | MPL, THPO, PFKP | LDHA 3588/4885RCE1 2347/4885PTPN22 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.